, a bio/informatics shared resource is still "open for business" - Visit the CDS website

Tiffany D Farmer, MS

Official Affiliation: Diabetes Research and Training Center (DRTC)

Profile

Tiffany graduated from DePauw University with a Bachelors degree in Biology in 2002.  She worked at Eli Lilly doing diabetes research for a year before moving to Nashville to work at Vanderbilt in Alan Cherrington's lab.  In 2008 Tiffany began working and managing the newly developed Rat Metabolic Physiology Sub-Core (RMPC) and in 2009 she received a Masters degree.

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Comparison of the physiological relevance of systemic vs. portal insulin delivery to evaluate whole body glucose flux during an insulin clamp. Farmer TD, Jenkins EC, O'Brien TP, McCoy GA, Havlik AE, Nass ER, Nicholson WE, Printz RL, Shiota M (2015) Am J Physiol Endocrinol Metab 308(3): E206-22
    › Primary publication · 25516552 (PubMed) · PMC4312835 (PubMed Central)
  2. Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dog. Moore MC, Werner U, Smith MS, Farmer TD, Cherrington AD (2013) Am J Physiol Endocrinol Metab 305(12): E1473-82
    › Primary publication · 24148347 (PubMed) · PMC3882379 (PubMed Central)
  3. Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog. Edgerton DS, An Z, Johnson KM, Farmer T, Farmer B, Neal D, Cherrington AD (2013) Am J Physiol Endocrinol Metab 305(1): E132-9
    › Primary publication · 23673158 (PubMed) · PMC3725568 (PubMed Central)
  4. Interaction between the central and peripheral effects of insulin in controlling hepatic glucose metabolism in the conscious dog. Ramnanan CJ, Kraft G, Smith MS, Farmer B, Neal D, Williams PE, Lautz M, Farmer T, Donahue EP, Cherrington AD, Edgerton DS (2013) Diabetes 62(1): 74-84
    › Primary publication · 23011594 (PubMed) · PMC3526039 (PubMed Central)
  5. Brain insulin action augments hepatic glycogen synthesis without suppressing glucose production or gluconeogenesis in dogs. Ramnanan CJ, Saraswathi V, Smith MS, Donahue EP, Farmer B, Farmer TD, Neal D, Williams PE, Lautz M, Mari A, Cherrington AD, Edgerton DS (2011) J Clin Invest 121(9): 3713-23
    › Primary publication · 21865644 (PubMed) · PMC3163950 (PubMed Central)
  6. Endogenously released GLP-1 is not sufficient to alter postprandial glucose regulation in the dog. Johnson KM, Farmer T, Schurr K, Patrick Donahue E, Farmer B, Neal D, Cherrington AD (2011) Endocrine 39(3): 229-34
    › Primary publication · 21547512 (PubMed) · PMC5371028 (PubMed Central)
  7. Insulin-induced hypoglycemia increases hepatic sensitivity to glucagon in dogs. Rivera N, Ramnanan CJ, An Z, Farmer T, Smith M, Farmer B, Irimia JM, Snead W, Lautz M, Roach PJ, Cherrington AD (2010) J Clin Invest 120(12): 4425-35
    › Primary publication · 21084754 (PubMed) · PMC2993579 (PubMed Central)
  8. Effect of 11 beta-hydroxysteroid dehydrogenase-1 inhibition on hepatic glucose metabolism in the conscious dog. Edgerton DS, Basu R, Ramnanan CJ, Farmer TD, Neal D, Scott M, Jacobson P, Rizza RA, Cherrington AD (2010) Am J Physiol Endocrinol Metab 298(5): E1019-26
    › Primary publication · 20159854 (PubMed) · PMC2867371 (PubMed Central)
  9. Portal infusion of escitalopram enhances hepatic glucose disposal in conscious dogs. An Z, Moore MC, Winnick JJ, Farmer B, Neal DW, Lautz M, Smith M, Rodewald T, Cherrington AD (2009) Eur J Pharmacol 607(1-3): 251-7
    › Primary publication · 19326481 (PubMed) · PMC2775505 (PubMed Central)
  10. Hepatic portal venous delivery of a nitric oxide synthase inhibitor enhances net hepatic glucose uptake. Moore MC, Dicostanzo CA, Smith MS, Farmer B, Rodewald TD, Neal DW, Williams PE, Cherrington AD (2008) Am J Physiol Endocrinol Metab 294(4): E768-77
    › Primary publication · 18212022 (PubMed)
  11. Intraportally delivered GLP-1, in the presence of hyperglycemia induced via peripheral glucose infusion, does not change whole body glucose utilization. Johnson KM, Edgerton DS, Rodewald T, Scott M, Farmer B, Neal D, Cherrington AD (2008) Am J Physiol Endocrinol Metab 294(2): E380-4
    › Primary publication · 18056788 (PubMed)
  12. Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels. Johnson KM, Edgerton DS, Rodewald T, Scott M, Farmer B, Neal D, Cherrington AD (2007) Am J Physiol Endocrinol Metab 293(4): E1085-91
    › Primary publication · 17684104 (PubMed)
View full member profile

Featured Affiliation

No featured affiliations

    View all affiliations

    Contact Information

    2213 Garland Avenue
    Vanderbilt University Medical Center
    7435 MRBIV
    Nashville, TN 37232
    615-343-5237 (p)
    Email

    Keywords & MeSH Terms

    MeSH terms are retrieved from PubMed records. Learn more.

    Key: MeSH Term Keyword

    3-Hydroxybutyric Acid Acetaminophen AMP-Activated Protein Kinases Analysis of Variance Animals Blood Glucose Carbon Catheterization Catheterization, Peripheral Diabetes Mellitus, Type 2 Enteroendocrine Cells Enzyme-Linked Immunosorbent Assay Enzyme Activation Exenatide Fatty Acids, Nonesterified Glucokinase Gluconeogenesis Glycerol Glycogen Synthase Kinase 3 Homeostasis Hyperglycemia Insulin Kinetics Lactic Acid Liver Glycogen Molsidomine Pancreatic Hormones Portal Vein Rats Somatostatin